Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: A case-control study

Gene

Volumn 527, Issue 2, 2013, Pages 601-605

  Fawzy, M S ^a   Aly, N M M ^a   Shalaby, S M ^a   El Sawy, W H ^a   Abdul Maksoud, R S ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Cyclooxygenase 2 gene; Plasma PGE2; Polymorphism

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E2;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

BC; BREAST CANCER; COX-2; CYCLOOXYGENASE-2 GENE; CYCLOOXYGENASES-2; ER; ESTROGEN RECEPTORS; IHC; IMMUNOHISTOCHEMICAL; PCR RFLP; PCR-RESTRICTION FRAGMENT LENGTH POLYMORPHISM; PG; PLASMA-PGE2; POLYMORPHISM; PR; PROGESTERONE RECEPTORS; PROSTAGLANDINS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84881548829     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.06.007     Document Type: Article

References (34)

1. Abeloff M.D., Wolff A.C., Weber B.L. Cancer of the breast. Clinical Oncology 2008, 1875-1943. Philadelphia. 4th ed.
2. Boland G.P., Butt I.S., Prasad R., Knox W.F., Bundred N.J. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer 2004, 90:423-429.
3. Cok S.J., Morrison A.R. The 3-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J. Biol. Chem. 2001, 276(25):23179-23185.
4. 3 levels in breast and ovarian cancer. Anticancer Res. 2012, 32(1):351-357.
5. Cox D.G., Buring J., Hankinson S.E., Hunter D.J. A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007, 9(1):R3.
6. Davies G.L.S. Cyclooxygenase-2 and chemoprevention of breast cancer. J. Steroid Biochem. Mol. Biol. 2003, 86:495-499.
7. Denkert C., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003, 97:2978-2987.
8. Denkert C., Winzer K.J., Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer 2004, 4:428-433.
9. Dossus L., et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010, 31(3):455-461.
10. Gallicchio L., et al. Nonsteroidal anti-inflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006, 106:1443-1452.
11. Gao J., et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J. Toxicol. Environ. Health A 2007, 70:908-915.
12. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
13. Hattersley A.T., McCarthy M.I. What makes a good genetic association study?. Lancet 2005, 366:1315-1323.
14. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007, 9(4):210.
15. Hu Z., et al. A common polymorphism in the 3' UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005, 48(1):11-17.
16. 2. J. Immunol. 2012, 188:121-128.
17. Langsenlehner U., et al. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin. Cancer Res. 2006, 12:1392-1394.
18. Leo C., Faber S., Hentschel B., Hfckel M., Lars-Christian S., Horn L. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann. Diagn. Pathol. 2006, 10:327-332.
19. Li F., Ren G.S., Li H.Y., Wang X.Y., Chen L., Li J. A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin. Oncol. 2009, 21:302-305.
20. Lin W.L., Lee Y.J., Wang S.M., Huang P.Y., Tseng T.H. Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B. Eur. J. Pharmacol. 2012, 680:8-15.
21. Liu C.H., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 2001, 276(21):18563-18569.
22. Malachi T., Chaimoff C., Feller N., Halbrechl I. Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J. Cancer Res. Clin. Oncol. 1981, 102:71-79.
23. Menter D.G., Schilsky R.L., DuBois R.N. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin. Cancer Res. 2010, 16:1384-1390.
24. Patrono C., Baigent C. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol. Interv. 2009, 9(1):31-39.
25. Piranda D.N., Festa-Vasconcellos J.S., Amaral L.M., Bergmann A., Vianna-Jorge R. Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 2010, 10:613.
26. Prosperi J.R., Robertson F.M. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat. 2006, 81:55-70.
27. Ranger G.S., Jewell A., Thomas V., Mokbel K. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J. Surg. Oncol. 2004, 88:100-103.
28. Sobolewski C., Cerella C., Dicato M., Ghibelli L., Marc J. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell Biol. 2010, 2010:215158.
29. Thill M., et al. Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer. Anticancer Res. 2010, 30(5):1673-1679.
30. Timoshenko A.V., Chakraborty C., Wagner G.F., Lala P.K. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br. J. Cancer 2006, 94(8):1154-1163.
31. Vogel U., Christensen J., Nexø B.A., Wallin H., Friis S., Tjønneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2007, 28(9):2062.
32. Watson J., Chuah S.Y. Prostaglandins, steroids and human mammary cancer. Eur. J. Cancer Clin. Oncol. 1985, 21(9):1051-1055.
33. Wülfing P., et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J. Cancer Res. Clin. Oncol. 2003, 129(7):375-382.
34. Zhu W., Wei B.B., Shan X., Liu P. 765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol. Biol. Rep. 2010, 37(1):277-288.